Lineage Cell Therapeutics Inc (XTAE:LCTX)
₪ 3.294 0.074 (2.3%) Market Cap: 632.94 Mil Enterprise Value: 497.81 Mil PE Ratio: 0 PB Ratio: 2.44 GF Score: 62/100

Lineage Cell Therapeutics Inc at B Riley Fall Growth Biotech Best Ideas (Virtual) Transcript

Oct 18, 2021 / 04:30PM GMT
Release Date Price: ₪7.49 (-1.10%)
Mayank Mamtani
B. Riley Financial, Inc. - Analyst

Hi. So we are welcoming you back to our Fall 2021 Best Idea series. This is the third chapter. My name is Mayank Mamtani. I'm a Senior Biotech Analyst representing the broader healthcare research efforts in trying to bring forward [health] growth ideas within the smid-cap space. This particular one focused within cell therapy. The name of the company is Lineage Cell Therapeutics, ticker LCTX, where I'm pleased to have with me members of the management team: Brian Culley, CEO; Kevin Cook, CFO; Gary Hogge, SVP, Clinical and Medical Affairs; and also very fortunate to be joined by Dr. Jordi Monés, a prominent KOL in the ophthalmology clinical development space. But his particular research is in macular and retinal degeneration. He currently serves as the director in Institut de la Mà cula and a principal investigator with the Barcelona Macula Foundation: Research for Vision.

Thank you, everyone, for joining us. Before we get started, need to make a quick set of disclosures. In the normal course of business, B. Riley Securities seeks to perform

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot